The Center for Vaccine Development seeks volunteers between the ages of 18 and 45 for a study involving an investigational tuberculosis (TB) vaccine. Those who have received the BCG vaccine are not eligible to participate. Volunteers will be compensated after each completed visit for time and travel; the study is expected to last approximately six months with 15-18 visits.
Background and Purpose:
Tuberculosis has been declared a global health emergency by the World Health Organization. Mycobacterium tuberculosis (Mtb) is the primary cause of TB and infects nearly one third of the world's population. TB is responsible for eight million new cases, as well as two million deaths each year, making it one of the world's most deadly infectious agents and one that causes more adult deaths than any other pathogen.
Bacillus Calmette-Guerin (BCG) is a vaccine that is used to protect against TB infection and complications. Current standard BCG vaccines have been used for approximately 60 years, are relatively safe and inexpensive to make, and help protect people against the worst forms of TB disease. However, they do not prevent infection, chronic latent (inactive) TB infection or the risks of TB disease progression. Worldwide, there is a great need for a more effective vaccine against TB.
The purpose of this study is to facilitate the development of tests for measuring BCG shedding from intradermal (shot given right underneath the skin) sites and to optimize tests for the measurement of systemic (whole body) inflammation (body's response to infection or injury).
To learn more about this study or other studies by contacting the Center for Vaccine Development at 314-977-6333 or 1-866-410-6333 (toll free) or email@example.com, or visiting its website. Refer to study number 294.